Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.72 |
| ▸ | IKZF3 | Q9UKT9 | 13/20 | 0.72 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 4/20 | 0.58 |
| ▸ | IL1B | P01584 | 4/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25225443 | 1.00 | CRBN (0.72) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL25225393 | 0.92 | CRBN (0.62) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL21848719 | 0.88 | CRBN (0.61) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL24967104 | 0.87 | CRBN (0.63) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL25272444 | 0.87 | CRBN (0.71) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL31076618 | 0.87 | CRBN (0.71) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL19585322 | 0.86 | CRBN (0.64) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL31055108 | 0.86 | IKZF2 (0.58) | CRBNIKZF3IKZF2TNFIL1B | |
| SCHEMBL25647408 | 0.86 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25236707 | 0.85 | CRBN (0.61) | CRBNIKZF3IKZF2TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |